Mean values for platelet aggregation phenotypes by PEAR1 rs12041331 genotype (AA, AG, GG) in participants of EA and African ancestry
| . | EA . | African ancestry . | ||||||
|---|---|---|---|---|---|---|---|---|
| AA, mean ± SD (N) . | AG, mean ± SD (N) . | GG, mean ± SD (N) . | PVL, % . | AA, mean ± SD (N) . | AG, mean ± SD (N) . | GG, mean ± SD (N) . | PVL, % . | |
| Phenotype after aspirin | ||||||||
| Col2 | 4.9 ± 7.8 (10) | 10 ± 12 (205) | 15 ± 13 (1026) | 2.92 | 4.9 ± 7.7 (113) | 14 ± 16 (373) | 20 ± 19 (349) | 6.57 |
| Col5 | 11 ± 11 (10) | 24 ± 19 (204) | 32 ± 21 (1023) | 2.58 | 14 ± 16 (112) | 29 ± 23 (368) | 37 ± 24 (342) | 8.08 |
| ADP2 | 15 ± 13 (10) | 32 ± 17 (187) | 36 ± 17 (912) | 1.35 | 25 ± 16 (107) | 31 ± 17 (359) | 38 ± 18 (326) | 7.09 |
| ADP10 | 57 ± 19 (10) | 66 ± 13 (202) | 69 ± 13 (992) | 0.712 | 58 ± 16 (112) | 65 ± 14 (368) | 71 ± 12 (339) | 7.14 |
| Epi2 | 13 ± 7.7 (10) | 18 ± 11 (205) | 23 ± 12 (1025) | 2.95 | 10 ± 8 (113) | 17 ± 11 (373) | 25 ± 17 (349) | 14.6 |
| Epi10 | 17 ± 8 (10) | 25 ± 14 (204) | 30 ± 14 (1021) | 2.28 | 14 ± 10 (112) | 22 ± 13 (369) | 31 ± 18 (341) | 13.6 |
| Phenotype at baseline | ||||||||
| Col2 | 43 ± 36 (10) | 61 ± 32 (205) | 66 ± 28 (1016) | 0.110 | 43 ± 35 (112) | 62 ± 31 (374) | 69 ± 26 (354) | 1.88 |
| Col5 | 69 ± 33 (10) | 81 ± 19 (205) | 83 ± 17 (1015) | 0.616 | 70 ± 29 (110) | 81 ± 21 (373) | 85 ± 15 (354) | 1.43 |
| ADP2 | 23 ± 20 (10) | 37 ± 25 (188) | 46 ± 26 (901) | 1.69 | 30 ± 26 (106) | 37 ± 28 (352) | 47 ± 28 (330) | 5.50 |
| ADP10 | 73 ± 25 (10) | 76 ± 16 (202) | 80 ± 14 (1004) | 0.854 | 69 ± 19 (112) | 74 ± 19 (373) | 80 ± 15 (351) | 4.28 |
| Epi2 | 32 ± 39 (10) | 47 ± 36 (205) | 57 ± 33 (1012) | 1.85 | 27 ± 33 (111) | 46 ± 35 (373) | 62 ± 34 (353) | 9.92 |
| Epi10 | 45 ± 38 (10) | 66 ± 31 (205) | 72 ± 27 (1012) | 1.15 | 39 ± 37 (112) | 61 ± 34 (374) | 72 ± 30 (354) | 7.22 |
| . | EA . | African ancestry . | ||||||
|---|---|---|---|---|---|---|---|---|
| AA, mean ± SD (N) . | AG, mean ± SD (N) . | GG, mean ± SD (N) . | PVL, % . | AA, mean ± SD (N) . | AG, mean ± SD (N) . | GG, mean ± SD (N) . | PVL, % . | |
| Phenotype after aspirin | ||||||||
| Col2 | 4.9 ± 7.8 (10) | 10 ± 12 (205) | 15 ± 13 (1026) | 2.92 | 4.9 ± 7.7 (113) | 14 ± 16 (373) | 20 ± 19 (349) | 6.57 |
| Col5 | 11 ± 11 (10) | 24 ± 19 (204) | 32 ± 21 (1023) | 2.58 | 14 ± 16 (112) | 29 ± 23 (368) | 37 ± 24 (342) | 8.08 |
| ADP2 | 15 ± 13 (10) | 32 ± 17 (187) | 36 ± 17 (912) | 1.35 | 25 ± 16 (107) | 31 ± 17 (359) | 38 ± 18 (326) | 7.09 |
| ADP10 | 57 ± 19 (10) | 66 ± 13 (202) | 69 ± 13 (992) | 0.712 | 58 ± 16 (112) | 65 ± 14 (368) | 71 ± 12 (339) | 7.14 |
| Epi2 | 13 ± 7.7 (10) | 18 ± 11 (205) | 23 ± 12 (1025) | 2.95 | 10 ± 8 (113) | 17 ± 11 (373) | 25 ± 17 (349) | 14.6 |
| Epi10 | 17 ± 8 (10) | 25 ± 14 (204) | 30 ± 14 (1021) | 2.28 | 14 ± 10 (112) | 22 ± 13 (369) | 31 ± 18 (341) | 13.6 |
| Phenotype at baseline | ||||||||
| Col2 | 43 ± 36 (10) | 61 ± 32 (205) | 66 ± 28 (1016) | 0.110 | 43 ± 35 (112) | 62 ± 31 (374) | 69 ± 26 (354) | 1.88 |
| Col5 | 69 ± 33 (10) | 81 ± 19 (205) | 83 ± 17 (1015) | 0.616 | 70 ± 29 (110) | 81 ± 21 (373) | 85 ± 15 (354) | 1.43 |
| ADP2 | 23 ± 20 (10) | 37 ± 25 (188) | 46 ± 26 (901) | 1.69 | 30 ± 26 (106) | 37 ± 28 (352) | 47 ± 28 (330) | 5.50 |
| ADP10 | 73 ± 25 (10) | 76 ± 16 (202) | 80 ± 14 (1004) | 0.854 | 69 ± 19 (112) | 74 ± 19 (373) | 80 ± 15 (351) | 4.28 |
| Epi2 | 32 ± 39 (10) | 47 ± 36 (205) | 57 ± 33 (1012) | 1.85 | 27 ± 33 (111) | 46 ± 35 (373) | 62 ± 34 (353) | 9.92 |
| Epi10 | 45 ± 38 (10) | 66 ± 31 (205) | 72 ± 27 (1012) | 1.15 | 39 ± 37 (112) | 61 ± 34 (374) | 72 ± 30 (354) | 7.22 |
PVL indicates proportion of total phenotypic variance attributable to the locus; Col2 and 5, aggregation to collagen 2 and 5 μg/mL, respectively; ADP2 and 10, aggregation to ADP 2 and 10μM, respectively; and Epi2 and 10, aggregation to epinephrine 2 and 10 μM, respectively